A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF THE COMBINATION OF NKTR-214 AND NIVOLUMAB OR THE COMBINATION OF NKTR-214, NIVOLUMAB, AND OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES

In this four-part study, NKTR-214 was administered in combination with nivolumab and
with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 +
nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the
doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet
therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214
+ nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet
combination at dosing schedules from Part 3.

INCLUSION CRITERIA - For Parts 1-4:

- Histologically confirmed diagnosis of a locally advanced (not amenable to curative
therapy such as surgical resection) or metastatic solid tumors

- Life expectancy > 12 weeks

- Patients must not have received prior interleukin-2 (IL-2) therapy

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Measurable disease per RECIST 1.1

- Patients with stable brain metastases under certain criteria

- Fresh and archival tumor tissue available Tumor specific inclusion criteria may apply.

EXCLUSION CRITERIA - For Parts 1-4:

- Use of an investigational agent or an investigational device within 28 days before
administration of first dose of NKTR--214

- Females who are pregnant or breastfeeding

- Participants who have an active autoimmune disease requiring systemic treatment within
the past 3 months or have a documented history of clinically severe autoimmune disease
that requires systemic steroids or immunosuppressive agents

- History of organ transplant that requires use of immune suppressive agents

- Active malignancy not related to the current diagnosed malignancy

- Evidence of clinically significant interstitial lung disease or active, noninfectious
pneumonitis

- Participants who have had < 28 days since the last chemotherapy, biological therapy,
or < 14 days from approved tyrosine kinase inhibitor (TKI) therapy, or systemic or
inhaled steroid therapy at doses greater than 10mg of prednisone Tumor specific
exclusion criteria may apply.

Other protocol defined inclusion/exclusion criteria may apply